Welcome to our dedicated page for DBV Technologies news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on DBV Technologies stock.
DBV Technologies S.A. develops treatment options for food allergies and other immunologic conditions as a late-stage biopharmaceutical company. Company updates center on the proprietary VIASKIN® patch technology, epicutaneous immunotherapy, and the VIASKIN Peanut program for peanut-allergic toddlers and children.
Recurring developments include clinical data from the Phase 3 VITESSE study, annual and quarterly financial results, financing and warrant-related capital actions, leadership and governance changes, share and voting-rights disclosures under French market rules, and market information tied to DBVT American Depositary Shares.
DBVT announced its monthly update on voting rights and total shares as of September 30, 2021. The company disclosed a total of 55,011,687 shares outstanding, with 54,936,287 shares having voting rights. This report follows Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. The data is crucial for shareholders and investors to monitor ownership and voting power within the company.
DBVT announced the voting rights and total shares as of August 31, 2021. The company holds 55,011,687 total shares, with a total gross of 55,011,687 voting rights and a total net of 54,963,687 voting rights, accounting for shares without voting rights. This data is provided in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. The shares are listed on the NYSE Euronext Paris market, under the ISIN Code: FR 0010417345.
DBV Technologies (DBVT) has announced participation in several virtual investor conferences in September 2021. The events include the Goldman Sachs Eleventh Annual Biotech Symposium on September 7, followed by Citi's 16th Annual BioPharma Virtual Conference on September 8. Additionally, a pre-recorded fireside chat will be made available on September 13 at 7:00 AM ET during the H.C. Wainwright 23rd Annual Global Investment Conference. Investors can access the webcast and replay on the company’s website.
DBVT has released its monthly update regarding the total number of shares and voting rights as of July 31, 2021. The total number of shares is reported at 55,011,687, while the total number of voting rights stands at 55,011,687 gross and 54,942,087 net. This update is in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. The company's ISIN code is FR 0010417345.
DBV Technologies (Euronext: DBV – Nasdaq: DBVT) has released its Half-Year report detailing its liquidity contract with ODDO BHF as of June 30, 2021. The liquidity account held 77,875 shares and €480,481.63 in assets, compared to 24,313 shares and €682,454.94 at the contract's inception in July 2018. During the second half of 2020, a total of 1,105 purchases and 1,146 sales were executed, with 461,457 shares bought for €4.3 million and 495,884 shares sold for €4.5 million.
DBV Technologies reported its second quarter 2021 financial results on August 2, 2021, highlighting progress in the development of its Viaskin Peanut patch. The company submitted a protocol for a critical study to the FDA and completed an adhesion trial, selecting two superior patch designs. Cash and cash equivalents stood at $125.5 million, down from $196.4 million at year-end 2020, expected to support operations until mid-2022. DBV's net loss narrowed to $30.7 million for Q2 2021, down from $48.2 million the previous year, with significant reductions in operating expenses attributed to budget discipline measures.
DBV Technologies, a clinical-stage biopharmaceutical company, will report its first half 2021 financial results and business updates on August 2, 2021. A conference call and live audio webcast will take place at 5:00 p.m. ET. Viaskin™, the company's investigational platform for immunotherapy, aims to transform the care of food allergic patients, with ongoing trials for Viaskin Peanut. The presentation will be available on their website, along with a replay post-event.
As of June 30, 2021, the total number of shares for the company was 55,011,687. This included 54,933,812 voting rights after accounting for shares without voting rights. This information is disclosed in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers and is crucial for investors monitoring voting power and company governance. The data is available on the NYSE Euronext Paris market under the ISIN Code: FR 0010417345.
As of May 31, 2021, the company reported a total of 55,011,687 shares outstanding. The total gross voting rights are also at 55,011,687, while the net voting rights stand at 54,943,413. This announcement complies with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies, a clinical-stage biopharmaceutical company, announced that CEO Daniel Tassé will participate in two upcoming virtual investor conferences in June 2021. The first is at the Goldman Sachs Global Healthcare Conference on June 8, 2021, at 8:50am ET, followed by the JMP Life Sciences Conference on June 16, 2021, at 10:00am ET. A live webcast of these events will be available on the company's website, where replays will also be accessible later. DBV is focused on developing Viaskin™, a technology aimed at immunotherapy for food allergies.